Side-by-side comparison of AI visibility scores, market position, and capabilities
Simple PCR-based cancer diagnostics running on standard lab equipment to democratize complex disease detection; $7M raised May 2025 from YC S22 competing with Grail and Exact Sciences for accessible liquid biopsy.
Signatur Biosciences is a London-based diagnostics company developing simple PCR-based tests that can detect complex diseases like breast cancer and other conditions using standard qPCR machines already present in most clinical laboratories — making sophisticated molecular diagnostics as accessible and operationally simple as a COVID-19 PCR test. Founded in 2022 and a Y Combinator S22 graduate, Signatur raised $7 million in May 2025 to scale its affordable, point-of-care compatible diagnostic solutions that address critical accessibility gaps in cancer diagnostics.
SF AI healthcare administration automating medical coding, billing, and claims for clinics with 30% cost savings and 20% fewer denials; YC S23 $4.5M competing with Waystar for revenue cycle management automation.
Decoda Health is a San Francisco-based AI healthcare administration platform — backed by Y Combinator (S23) with $4.5 million raised from YC, Amino Capital, Bossa Nova Ventures, Cadenza Ventures, Graphene Ventures, and Orange Collective — providing medical clinics and healthcare providers with autonomous AI agents that handle medical coding, billing, claims submission, denial management, scheduling coordination, and patient payment collection, automating 80%+ of the repetitive administrative tasks that currently consume 30-40% of healthcare provider revenue in overhead costs. Founded in 2023 by Daniyal Afzal, James Oswald, and Kevin Cheng, Decoda's AI agents deliver 30% reduction in coding costs, 20% reduction in claim denials, and claims processing in seconds versus the days that manual coding and submission require.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.